Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study

Surendra, M; Raju, Sree Bhushan; Nimmagadda, Sridhar; Kiran, Bangillapati Vijay; Goli, R; Golla, Anvesh; Raju, Nagarajan

doi:10.1111/hdi.12604

Cited by 22 publications

(26 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SVR12 rates were high in a cohort study evaluating ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in patients with HCV genotype 1 and 4 infection, and all patients with moderate‐to‐severe renal impairment achieved an SVR (100%, n = 34/34) . Furthermore, the SVR12 rate was excellent (100% n = 19/19) in a small study in patients with end‐stage renal disease on hemodialysis and with HCV genotype 1 infection who received ledipasvir and sofosbuvir on alternate days for 12 weeks …”

Section: Efficacy In the Real‐world Settingmentioning

confidence: 99%

Treatment of hepatitis C: Results in real life

Hézode

2018

Liver International

View full text Add to dashboard Cite

show abstract

Section: Efficacy In the Real‐world Settingmentioning

confidence: 99%

Treatment of hepatitis C: Results in real life

Hézode

2018

Liver International

View full text Add to dashboard Cite

show abstract

“…Some studies described above report that kidney function may deteriorate, particularly with SOF‐based regimens and in cirrhotic patients and patients with baseline CKD stage 3 . Conversely, a study using SOF in patients with mild to moderate renal dysfunction (CKD stages 2 and 3) found no changes in patients' eGFR from baseline to 12 weeks post therapy …”

Section: Risk Of Kidney Injury With Daasmentioning

confidence: 98%

“…The safety of SOF in patients with CKD is still a matter of debate. So far, we only have information from a few case series with limited number of patients and different doses and frequency of administration of SOF …”

Section: Current Regimens Available For Patients Ckdmentioning

confidence: 99%

See 1 more Smart Citation

Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease

Ridruejo

Mendizábal

Silva

2018

Hemodialysis International

View full text Add to dashboard Cite

Hepatitis C virus infection (HCV) is highly prevalent in patients with chronic kidney disease (CKD) and kidney transplant recipients. Little information exists on treatment in patients with CKD stages 2 to 3, where CKD progression might be slowed by HCV treatment. These patients are not considered a high priority for HCV treatment in most international guidelines. Although some recently published guidelines propose universal treatment, others are still recommending it only in high priority groups. In this review, we evaluate current evidence of HCV infection impact on CKD progression, on cardiovascular and metabolic risk, and the benefits of HCV infection treatment to improve cardiovascular and metabolic outcomes. We made special focus on the benefits of HCV infection treatment in patients with stages 2 to 3 CKD to avoid CKD progression.

show abstract

“…Bu çalışmanın amaçları; HCV pozitif hemodiyaliz hastalarında paritaprevir/ ritonavir/ombitasvir/dasabuvir (PROD), ledipasvir/sofosbuvir (LDV/SOF) ve peginterferon (Peg-IFN) alfa-2a tedavilerinin HCV enfeksiyonunu elimine etmedeki başarısını ve DEA alan hastaların eş zamanlı ilaç-ilaç etkileşimleri yönetiminin değerlendirilmesi amaçlanmıştır. Glomerüler filtrasyon hızı (GFH)<30 mL/dakika ileri evre kronik böbrek hastalığı (KBH) olan hastalarda SOF içeren bir tedavi rejiminin kullanımı ile ilgili veriler sınırlıdır, ancak HCV ile enfekte hemodiyaliz hastalarında SOF içeren kombinasyon tedavisinin etkin, güvenilir ve iyi tolere edildiği ile ilgili veriler literatürde mevcuttur (15,(22)(23)(24). 2018 Kidney disease: Improving Global Outcomes (KDIGO) kılavuzunda, HCV ile enfekte diyaliz hastalarında ribavirinsiz, DEA bazlı bir tedavi önermektedir.…”

Section: Introductionunclassified

Chronic Hepatitis C Virus Infection in Hemodialysis Patients: Treatment Outcomes and Drug-drug Interactions Management

Erdogmus¹

2019

atfm

View full text Add to dashboard Cite

The aim of this study was to evaluate the success of the paritaprevir/ritonavir/ombitasvir/dasabuvir (PROD), ledipasvir/sofosbuvir (LDV/ SOF) and peginterferon (Peg-IFN) alfa-2a in the elimination of chronic hepatitis C virus (HCV) infection in HCV positive hemodialysis patients, and to assess the management of concomitant drug-drug interactions in patients receiving direct acting antiviral (DAA). Materials and Methods: The demographical characteristics, comorbid diseases, laboratory data, and treatment regimen and duration of 10 patients who were infected with HCV genotype 1 were retrospectively screened from the electronic hospital records. The patients were divided into 3 groups according to treatment regimen: PROD, LDV/SOF and Peg-IFN. Data on virologic response, adverse events, and biochemical and hematological parameters during and after therapy were analyzed. Also, concomitant drug use and drug-drug interactions were evaluated in patients receiving DAA regimen. Results: The median age was 48 (21-74) years, 5 (50%) of patients were female. 2 patients (20%) received LDV/SOF, 5 (50%) PROD and 3 (30%) Peg-IFN. Six of patients (60%) were HCV treatment-experienced and were failed to previous Peg-IFN therapy. All patients achieved sustained virologic response (100%). At the end of the one-year follow-up period, none of patients presented with HCV reactivation, and thus HCV was eliminated from our hemodialysis unit. No patient experienced serious adverse event leading to medication discontinuation during the course of treatment. Drug-drug interactions had to be modified with the treatment initiation in 2 out of 7 patients who received DAA.

show abstract

Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study

Abstract: Ledipasvir and Sofosbuvir combination therapy on alternate days, is effective even in ESRD patients, with excellent SVR12 rates, and it is as safe as in other population groups, without any major adverse reactions.

Cited by 22 publications

References 20 publications

Treatment of hepatitis C: Results in real life

Treatment of hepatitis C: Results in real life

Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease

Chronic Hepatitis C Virus Infection in Hemodialysis Patients: Treatment Outcomes and Drug-drug Interactions Management

Contact Info

Product

Resources

About